Favipiravir in Covid-19

Suranjith L. Seneviratne, Visula Abeysuriya, Sanjay De Mel, Ishan De Zoysa, Roshan Niloofa

Abstract


The SARS-Cov-2 virus, emerged in December 2019 in Wuhan, China and has now spread to all parts of the world. Many research groups are carrying out intense research on drugs and vaccines to treat or prevent Covid-19. We have outlined aspects relating to Favipiravir, in treating RNA viral infections and its potential role in controlling SARS-Cov-2 infections.


Keywords


SARS-Cov-2; Covid-19; Favipiravir; drugs

Full Text:

PDF

References


Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020.

Furata Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase Proc Jpn Acad Ser B Phys Biol Sci 2017; 93(7): 449–463.

Tanaka T, Kamiyama T, Daikoku T, Takahashi K, Nomura N, Kurokawa M etal. T-705 (Favipiravir) suppresses tumour necrosis factor alpha production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug. Acta Virol, 2017; 61, 48-55.

Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM et al. Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis 2016; 63: 1288-1294.

Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK et al. Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. Clin Infect Dis 2017; 65: 855-859.

Yamada K, Noguchi K, Komeno t, Furata Y, Nishizono A. efficacy of Favipiravir in rabies post-exposure prophylaxis. J Infect Dis 2016; 213(8): 1253 – 61.

Ruis C, Brown LK, Roy S, Atkinson C, Williams R, Burns SO et al. Mutagenesis in Norovirus in Response to Favipiravir Treatment. N Engl J Med 2018, 379, 2173-2176.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCov) in vitro. Cell research 2020; 30: 269 -271

Cai, Q, Yang M, Liu D, Chen J, Shu D, Xia J et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering 2020.

Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv 2020.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Suranjith L. Seneviratne, Visula Abeysuriya, Sanjay De Mel, Ishan De Zoysa, Roshan Niloofa

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.